Moderna shares soar over 50% on melanoma drug trial success
Moderna's shares rose over 50% in pre-market trading after its melanoma drug, combined with Merck's Keytruda, showed success in a Phase 3 trial. The trial met primary and key secondary endpoints, showing improved recurrence-free and metastasis-free survival. This is the first positive Phase 3 result for an mRNA-based cancer therapy. Both companies plan to present data to regulators and at medical meetings. They are also conducting trials for other cancer types.
How this was made
The 30-second read
Why it matters
The trial met its primary endpoint of recurrence‑free survival and a key secondary endpoint, marking the first pivotal success for an mRNA cancer therapy.
Market read
Breakthrough trial data drives a sharp pre‑market rally for Moderna and modest upside for Merck, with broader implications for mRNA oncology.
What to watch
Regulatory review timelines and manufacturing scale‑up could delay revenue realization.
Background
The INTerpath‑001 trial combined Moderna's investigational mRNA neoantigen therapy with Merck's Keytruda in resected melanoma patients.
Ticker impact
Moderna announced that its Phase 3 melanoma trial with Merck's Keytruda showed statistically significant improvements, driving a >50% pre‑market jump.
Expect continued upside as investors digest the trial success; potential 10‑15% rally in the next few days.
First Phase 3 readout for an mRNA cancer therapy, large pre‑market move, and clear commercial potential.
Merck's Keytruda was part of the successful melanoma combination trial, confirming its efficacy and supporting Merck's oncology pipeline.
Modest upside expected; Merck may see a 2‑4% lift as the news filters through.
Merck benefits as a partner, but the headline move is driven by Moderna.
Market effects
Strengthens the mRNA oncology niche and may lift peer biotech stocks.
Positive for US biotech sector; limited immediate effect elsewhere.
Highlights the potential of mRNA therapies globally, could spur investor interest in similar pipelines.
Counterpoint
Skeptics may question long‑term commercial viability and pricing of an mRNA cancer combo.
Key entities
- CompanyModerna Inc
Developer of the mRNA neoantigen therapy.
- CompanyMerck & Co.
Provider of Keytruda, partner in the trial.
